Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | GALR3 | O60755 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12309232 | 0.86 | ALDH1A1 (0.60) | ALDH1A1LMNAKMT2ATSHRMEN1 | |
| SCHEMBL2458183 | 0.85 | ALDH1A1 (0.56) | ALDH1A1LMNAKMT2ATSHRMEN1 | |
| SCHEMBL12309234 | 0.85 | ALDH1A1 (0.58) | ALDH1A1LMNAKMT2ATSHRMEN1 | |
| SCHEMBL13949682 | 0.85 | ALDH1A1 (0.65) | ALDH1A1LMNAKMT2ATSHRMEN1 | |
| SCHEMBL12309235 | 0.85 | ALDH1A1 (0.58) | ALDH1A1LMNAKMT2ATSHRMEN1 | |
| SCHEMBL12309259 | 0.81 | ALDH1A1 (0.55) | ALDH1A1LMNAKMT2ATSHRMEN1 | |
| SCHEMBL2460781 | 0.81 | ALDH1A1 (0.55) | ALDH1A1LMNAKMT2ATSHRMEN1 | |
| SCHEMBL2465059 | 0.81 | ALDH1A1 (0.58) | ALDH1A1LMNAKMT2ATSHRMEN1 | |
| SCHEMBL2466509 | 0.81 | ALDH1A1 (0.76) | ALDH1A1LMNAKMT2ATSHRMEN1 | |
| SCHEMBL3266128 | 0.81 | ALDH1A1 (0.59) | ALDH1A1LMNAKMT2ATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188293-B1 | 6-SUBSTITUTED SULFONYL AZABICYCLOÝ3.2.1¨OCTANES USEFUL TO INHIBIT 11 -HYDROXYSTEROID DEHYDROGENASE TYPE-1 | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| US-8466149-B2 | 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I | MERCK SHARP & DOHME CORP. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466149-B2 | 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I | MERCK SHARP & DOHME CORP. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110237559-A1 | 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237559-A1 | 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2009023181-A1 | 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11β-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237559-A1 | 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | HSD17B1, HSD11B1, HSD17B11 | ALDH1A1 29/4885LMNA 3130/4885KMT2A 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.